Effects of EEG- Microstate Neurofeedback on Attention and Impulsivity in Adult Attention-deficit/Hyperactivity Disorder (ADHD) and Neurotypical Controls

Launched by NADER PERROUD · Oct 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for adults with Attention-deficit/Hyperactivity Disorder (ADHD) using a method called EEG neurofeedback. EEG neurofeedback is a technique that helps individuals learn to control certain brain activity patterns. The researchers want to see if this method can improve attention and reduce impulsivity in people with ADHD, as well as in healthy individuals without the disorder. The study will also look at how changes in brain activity relate to these behaviors.

To participate in this trial, you need to be between 18 and 50 years old and in generally good health. If you have ADHD, you should be able to stop certain medications for 48 hours before participating. Healthy individuals cannot have a history of ADHD or significant mental health issues. Participants will receive training on how to use the EEG neurofeedback and will be monitored for changes in attention and impulsivity. This trial is currently recruiting, and your involvement could help researchers understand more about ADHD and how to treat it effectively.

Gender

ALL

Eligibility criteria

• • ADHD POPULATION GROUP
• A subject will be eligible if all the following criteria apply:
• • Age: between 18-50 years
• • Gender: male and female
• • Health: general good health and normal or corrected-to-normal visual acuity
• • Patients clinically able to stop the following psychotropic medications for 48h: psychostimulants, benzodiazepines
• • Having provided written informed written consent
• A subject will not be eligible if any of the following criteria apply:
• • Past or current history of a clinically significant central nervous system disorder, including structural brain abnormalities; cerebrovascular disease; history of other neurological disease, epilepsy, stroke or head trauma (defined as loss of consciousness \> 5 min or requiring hospitalization)
• • Impaired vision (normal or corrected acuity below 20/40)
• • Medical illness (e.g., cardiovascular disease, renal failure, hepatic dysfunction)
• • Comorbidities with current psychiatric disorders (bipolar disorder, borderline personality disorder, major depressive disorder, anxiety disorder) including substance use disorder as defined by the DIGS.
• • HEALTHY POPULATION GROUP
• A subject will be eligible if all of the following criteria apply:
• • Age: between 18-50 years
• • Gender: male and female
• • Health: general good health and normal or corrected-to-normal visual acuity
• • Having provided written informed written consent
• A subject will not be eligible if any of the following criteria apply:
• • Past or current history of ADHD
• • Past or current history of main psychiatric disorders (bipolar disorder, borderline personality disorder, major depressive disorder, anxiety disorder), including substance use disorder as defined by the DIGS.
• • Past or current history of a clinically significant central nervous system disorder, including structural brain abnormalities; cerebrovascular disease; history of other neurological disease, including epilepsy, stroke or head trauma (defined as loss of consciousness \> 5 min or requiring hospitalization)
• • Impaired vision (normal or corrected acuity below 20/40)
• • Medical illness (e.g., cardiovascular disease, renal failure, hepatic dysfunction)